Goldilocks Dosing of TKIs: A Dose that is Just Right Leads to Optimal Outcomes

Higher concentrations of TKIs such as pazopanib are associated with improved outcomes in advanced RCC. A phase 3 trial failed to show disease-free survival benefit to pazopanib in the adjuvant setting, but improved DFS was seen in patients with higher Ctrough levels, supporting adequate drug exposure for optimal clinical outcome.

from Cancer via ola Kala on Inoreader http://ift.tt/2FrxgOt
via IFTTT